Research advances in hepatic fibrosis related signal pathways and anti-hepatic fibrosis drugs
10.3969/j.issn.1001-5256.2022.05.039
- VernacularTitle:肝纤维化相关信号通路及其相应的抗肝纤维化药物研究进展
- Author:
Suriguga LU
1
;
Ting LIU
1
;
Dandan ZHU
1
;
Sijia YU
1
;
Liqing LU
1
;
Junjie DING
1
Author Information
1. Xiangya Hospital of Central South University, Changsha 410000, China
- Publication Type:Reviews
- Keywords:
Liver Cirrhosis;
Hepatic Stellate Cell;
Signal Transduction;
Drug Therapy
- From:
Journal of Clinical Hepatology
2022;38(5):1161-1164
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic fibrosis is a pathological process in which the liver is subjected to various acute and chronic injuries for a long time, resulting in activation of hepatic stellate cells, the imbalance between the production and degradation of extracellular matrix, and the deposition of extracellular matrix in the liver, and it is jointly controlled by multiple cellular signal transduction pathways and a series of cellular information molecular networks. If there is no effective treatment, with the progression of the disease, liver fibrous nodules will form, destroy normal liver structure and function, and finally develop into liver cirrhosis, the decline of liver function, and even liver cancer. This article summarizes the research advances in the signaling pathways, receptors, and non-coding RNAs involved in liver fibrosis and the corresponding anti-hepatic fibrosis drugs/molecules.
